Altimmune bails on hepatitis B after phase 2 data disappoint, quashing partnering plans

Altimmune has been beaten by hepatitis B. The drug candidate, which the company was preparing for partnering, failed to meet the bar for further development in a phase 2 study, prompting the biotech to stop development and focus on its GLP-1/glucagon dual receptor agonist.